A Third OTC Naloxone Brand Won't Save Anyone Whose Kit Is in a Drawer at Home

Somebody goes down in a gas station bathroom, or a car parked two blocks from home, or a friend’s couch at 2 a.m. The naloxone that could reverse it is real, paid for, sitting in a nightstand drawer across town. That’s not a hypothetical. That’s the median outcome, according to the data on who actually carries the drug versus who merely owns it.

On June 16, 2026, the FDA approved Rextovy, a 4 mg naloxone HCl nasal spray from Amphastar Pharmaceuticals, as the third over-the-counter reversal product on the market alongside Narcan and RiVive. The FDA’s framing is right as far as it goes: more approved formulations means more manufacturers competing for shelf space, which historically pushes price down and supply up. The agency’s own release notes that overdose deaths have fallen from 111,451 to 68,632 annually since the first OTC naloxone nasal spray hit shelves in 2023 — a real, staggering drop, even if it has more causes than any one product launch.

The naloxone shortage in this country was never really a supply problem — it’s a pockets problem.

A study published in the International Journal of Drug Policy, following 780 people who use opioids in Baltimore, found that 78.2% of them reported owning naloxone. That’s the headline number every approval story leans on, and it sounds like a solved problem. It isn’t. Only 27.0% of that same group were actually carrying naloxone on them at the moment they were surveyed. The other 69.4% kept it at home — which is exactly nowhere, if the overdose happens at a dealer’s apartment, a rest stop, a friend’s basement, or literally anywhere that isn’t the residence with the drawer.

Rextovy doesn’t touch that gap. Neither did Narcan’s OTC switch in 2023, and neither will the next nasal spray or auto-injector that clears FDA review. Approval solves distribution. Distribution solves ownership. Ownership is not carry. A harm reduction worker handing out kits at a syringe exchange can put naloxone in someone’s hand every week and still watch it end up in a backpack that stays home, because carrying an overdose antidote means carrying a daily reminder that you or someone you love might die today — and most people, understandably, don’t want that reminder on their body.

This is a behavior and design problem, not a policy one at this point. It means normalizing naloxone the way people normalize keys and a phone — on you, not near you. It means harm reduction programs measuring carry rates, not just distribution counts. It matters more now that fentanyl has cut the margin for error to almost nothing, and more now that adulterants like medetomidine are already complicating what naloxone can reverse once it’s actually deployed.

A third brand on the shelf is good news. It is not the news. The overdose that kills someone this week won’t happen in the room where their naloxone lives.